QUANTIFICATION OF EXEMESTANE ACCUMULATION DURING MICROBIAL BIOCONVERSION BY TLC IMAGE ANALYSIS
Objective: The present study was aimed at developing a rapid, cost effective and accurate method for quantification of exemestane using thin layer chromatography (TLC) separation followed by image analysis and to test it for monitoring the accumulation of exemestane during microbial bioconversion.
Methods: After microbial bioconversion and TLC separation of products formed, exemestane was quantified using ImageQuant TL v2003 image analysis software and the results were compared with high performance liquid chromatography (HPLC) analysis.
Results: The percentage error between TLC and HPLC analyses was ranged from (-) 5.18 to (+) 5.51. Bacterial strains Arthrobacter simplex IAM 1660, Nocardia sp. MTCC 1534, Pseudomonas putida MTCC 1194 and Rhodococcus rhodochorus MTCC 291 respectively yielded 79.7 (72 h), 63.9 (72 h), 69.8 (96 h) and 83.2 (96 h) mole percent bioconversion of 6-methylene androstenedione to exemestane.
Conclusion: Rhodococcus rhodochorus MTCC 291 was found to be the most suitable organism for the bioconversion and may be used to develop an eco-friendly route to replace chemical synthesis that eliminates the use of toxic chemicals and side products.
2. Goss PE, Ingle JN, AlÃ©s-MartÃnez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-91.
3. TrÃ©dan O, Follana P, Moullet I, Cropet C, et al. A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study. Ann Oncol 2016;27:1020-9.
4. Agarwal VK, Singh MK, Patel AM. Process for preparing aromatase inhibitor exemestane. US Patent: 8288571; 2012.
5. Buzzetti F, Barbugian N, Lombardi P. 6-substituted androsta-1,4-diene-3,17-dione. US Patent: 4808616; 1989.
6. Longo A, Lombardi P. Process for the preparation of methylene derivatives of androsta-1, 4-diene-3, 17-dione. US Patent: 4876045; 1989.
7. Kunnen K, Stehle NW, Weis SW, Pascone JM. Exemestane and its intermediates and methods of making the same. US Patent: 8183401; 2012.
8. Agarwal VK, Singh MK, Patel AM. Process for preparing aromatase inhibitor exemestane. PCT Patent: WO 2009/093262A2; 2009.
9. Marcos-Escribano A, Bermejo FA, Bonde-Larsen AL, Retuerto JI, Sierra IH. 1, 2-Dehydrogenation of steroidal 6-methylen derivatives. Synthesis of exemestane. Tetrahedron 2009;65:7587-90.
10. Sukhodolskaya GV, Fokina VV, Savinova TS, Shutov AA. Combined chemical and microbiological synthesis of exemestane from sitosterol. J Biotechnol 2010;30;150:89.
11. Savinova TS, Lukashev NV, Sukhodolskaya GV, Donova MV, et al. Method for obtaining 6-methyleneandrost-4-ene-3, 17-dione and obtaining of 6-methylene androsta-1, 4-diene-3, 17-dione (exemestane) from 6-methyleneandrost-4-ene-3, 17-dione thereof. Patent: RU2425052; 2011.
12. Patil P, Sharma R, Banerjee T, Patil S. Substrate carriers for C-1-dehydrogenation of 6-methylene androstenedione to exemestane by growing and immobilized Arthrobacter simplex NCIM 2449. Asian J Pharm Clin Res 2017;10:392-6.
13. Patil P, Sharma R, Banerjee T, Patil S. The C-1-dehydrogenation of 6-methylene androstenedione to exemestane, an aromatase inhibitor used for the treatment of breast cancer. Int J Appl Biol Pharm Technol 2017;8:107-11.
14. Mareck U, Geyer H, Guddat S, Haenelt N. Identification of the aromatase inhibitors anastrozole and exemestane in human urine using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2006;20:1954-62.
15. KsyciÅ„ska H, BuÅ›-KwaÅ›nik K, Szlagowska A, Rudzki PJ. Development and validation of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of exemestane in human plasma. J Chromatogra B 2011;879:1905-10.
16. Cavalcanti GD, Garrido BC, Leal FD, Padilha MC. Analysis of exemestane and 17Î²â€hydroxyexemestane in human urine by gas chromatography/mass spectrometry: development and validation of a method using MOâ€TMS derivatives. Rapid Commun Mass Spectrom 2010;24:3297-302.
17. Cenacchi V, Baratte S, Cicioni P, Frigerio E. LCâ€“MSâ€“MS determination of exemestane in human plasma with heated nebulizer interface following solid-phase extraction in the 96 well plate format. J Biomed Anal 2000;22:451-60.
18. Mane MB, Sangshetti JN, Wavhal PJ, Wakte PS. Determination of exemestane in bulk and pharmaceutical dosage form by HPTLC. Arabian J Chem 2014;7:504-8.
19. Yavuz B, Bilensoy E, Åžumnu M. Analytical method validation for HPLC assay of oral anticancer drug exemestane. J Pharm Sci 2007;32:15-22.
20. Kumar UK, Vinatha B, Sunitha P, Sushma GS. Method development and method validation of exemestane in bulk and pharmaceutical dosage form by RP-HPLC technique. J Sci Res Pharm 2012;1:115-7.
21. Mukthinuthalapati MA, Bukkapatnam V. A novel validated stability-indicating RP-HPLC method for the determination of exemestane (steroidal aromatase inhibitor). J Bioequivalence Bioavailability 2015;7:288-92.
22. Konda B, Tiwari RN, Fegade H. Development and validation of stability indicating method for the determination of exemestane by reverse phase high performance liquid chromatography. J Chromatogra Sci 2011;49:634-9.
23. Cimpoiu C, Hosu A, Hodisan S. Analysis of some steroids by thin-layer chromatography using optimum mobile phases. J Pharm Biomed Anal 2006;41:633-7.
24. Johnsson R, TrÃ¤ff G, SundÃ©n M, Ellervik U. Evaluation of quantitative thin layer chromatography using staining reagents. J Chromatogr A 2007;1164:298-305.
25. Poole CF. Planar chromatography at the turn of the century. J Chromatogra A 1999;856:399-427.
26. Poole CF. Thin-layer chromatography: challenges and opportunities. J Chromatogra A 2003;1000:963-84.
27. Gerasimov AV. Use of the software processing of scanned chromatogram images in quantitative planar chromatography. J Anal Chem 2004;59:348-53.
28. Borodina EV, Kitaeva TA, Safonova EF, Selemenev VF. Determination of Î±-tocopherol and ergocalciferol by thin-layer chromatography. J Anal Chem 2007;62:1064-8.
29. Jethva J, Pawar K, Shah J, Vyas J. Bioconversion of 11-Î², 17-Î±, 21-trihydroxy-4-pregnene-3, 20-dione, 21-o-succinate by actively growing culture of Pseudomonas putida MTCC 1259. Int J Appl Biol Pharm Technol 2011;3:167-72.
30. De las Heras LF, Van der Geize R, Drzyzga O, Perera J. Molecular characterization of three 3-ketosteroid-Î” 1-dehydrogenase isoenzymes of Rhodococcus ruber strain Chol-4. J Steroid Biochem Mol Biol 2012;1323:271-81.
31. Horinouchi M, Hayashi T, Yamamoto T, Kudo T. A new bacterial steroid degradation gene cluster in Comamonas testosteroni TA441 which consists of aromatic-compound degradation genes for seco-steroids and 3-ketosteroid dehydrogenase genes. Appl Environ Microb 2003;69:4421-30.
32. Kominek LA, Wolf HJ, Process for preparing 1, 2-dehydro steroids. US Patent: 4524134; 1985.
33. Gulla V, Banerjee T, Patil S. Quantitative TLC analysis of steroid drug intermediates formed during bioconversion of soysterols. Chromatographia 2008;68:663-7.
34. Pendharkar GB, Anjum SD, Patil S. Enhanced biotransformation of phytosterols, a byproduct of soybean refineries to a key intermediate used for synthesis of steroidal drugs. Asian J Pharm Clin Res 2014;7:178-80.
35. Pendharkar GB, Awadhiya PK, Banerjee T, Patil S. Effect of substrate concentration on the bioconversion of phytosterols to androst-4-ene-3,17-dione (AD) by Mycobacterium fortuitum subsp. fortuitum NCIM 5239. Int J Pharm Res Dev 2014;6:24-32.